































	Name:	Mala	- Famala	Type 2	Type 1	Age	at diagnosis:	
Diabatas Flow Shoot	Band #:	 Male 	- Female	Medical his	ory:			
Diabeles Flow Sheel	Healthcare Card #:	Diak Feata	an è Ca mashidit	Allergies:				
 BP, Wt. BMI 	Hypertension Dyslipidemia Polycystic ov	y disease arian syndroi	Corona Corona Erectile	ry artery dise dysfunction	ase □ P □ N	Periphera Mental illr	I artery disea	ise
• A1C	Retinopathy Substance m	Routine D	abetes Assessm	ent (every 3 t	o 6 months)		or quit-date	
Blood Glucoso (homo)	BP s130/80 for most							
	Wt (kg) / BMI / WC (cm) BMI 18.5-24.9							
 Foot Check 	A1C							
 Self-Mgmt Goals 	Blood Glucose (self-monitoring) Inquire about hypoglycemia for most personal 4.0.7 (mmobili)							
Nutrition	2-hour postmeal 5.0-10.0mmol/L Foot check (frequency based on							
Physical Activity	Any redness, open area, blister, sign of infection, etc							
Carabian Constitut	client							
 Smoking Cessation 	Nutrition (note referrals) Portion control/CHO consistency Healthy dietary patterns							
 Psychosocial 	Physical Activity Aerobic 2150min/week							
 Medications – review 	Smoking Cessation (if applicable)							
	Assess for diabetes-related distress, depression, anxiety, substance use, etc.							
Lab Results:	Medications - review Note any change(s) Inquire about traditional medicine(s)							
ACR. eGER	See progress notes	No change	No change	No char	ige ⊡No	change	No change	No chang
	Signature							
• LDL, HDL, IG	Screening for Diabetes C Nephropathy	Neurop	(annually or as bathy	ndicated, but	labwork mus	Ret	ered by NP or tinopathy	Vaccination
	Date ACR eGF	R Date: _	diabetes foot ass	essment form		Anrexa	nual eye im	Flu (annual): Date:
Annual Eve Exam		Screen	ing frequency: ry 3 months :	Yearly D E Every 1 to 3	very 6 montl months	hs Dat	e	Date:
Vaccinations		gastroi Date:	about neuropathi ntestinal symptom Find	c pain, erectile s ings:	dystunction,	040		Date:
vaccinations	For vascular protection: Statins if CVD, or 540 years, or >30 years	s Or >5	argets: If indicate 0% reduction (Res	d to treat LDL at in 3-6 months if	C <2.0 mmol. tx initiated to cont	/L Sel frm) Glu	f-monitoring cose	of Blood
	and >15 years duration, or microvascular disease	Date	Medication LDI	. HDL TG	(non- (A) HDL- B) C)	po Anr Dat	nual meter-to-la le:	ab comparisor
	organ damage, or microvascular disease CVD Assessment ECG	\vdash		+		Rev (hav	view client tech	inique trate with own
	Stress ECG:	. 🕂				Dat	ier) ie:	
liahataa	Updated May 2018	See rev	erse for care ob	ectives and t	rgets		C	CHCA 2













- Therefore, follow-up should focus on enabling the client to be able to selfmanage their diabetes and may occur every 4-6 weeks initially or more often as needed.
- Be careful not to overload the client with too much information
- All clients (and their families) should be screened for symptoms of psychological distress
- All clients should be considered for a pneumococcal immunization and annual influenza vaccine

© CHCA 2022 - RPN

21 of 38



Perform foot examination Every 6 months:
 If chronic kidney disease present (EGFR < 60 mL/min) at diagnosis in person with type 2 diabetes, perform random urine for albumin: creatinine ratio (ACR) and serum creatinine for estimated glomerular filtration rate (EGFR)



•	Many studies have noted that culturally appropriate care for diabetes is essential and requires a focus on the geographical, linguistic, educational and
	social differences among Indigenous peoples.
•	There is no evidence at present that therapeutic strategies should differ from those used in the general population.
Go	als of Treatment
•	Attain optimum glycemic control for type 1 or type 2.
	 Target FPG 4-7 mmol/L;
	 2-hour postprandial 5-10 mmol/L;
	 Hb_{A1C} ≤ 7%
•	Educate the client for self-care
•	Prevent complications
•	Attain optimum control of concomitant hypertension, dyslipidemia and other cardiovascular risk factors
•	Stop smoking



























